Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls.

ABSTRACT:

Objectives

To compare the risk of serious infection across time cohorts in patients with inflammatory arthritis (IA) initiating their first biologic/targeted synthetic DMARD (b/tsDMARD), to that of the general population. Secondarily, to compare the development in infection risk during treatment across diagnoses and examine risk dynamics during the course of b/tsDMARD treatment.

Methods

Patients with IA starting their first b/tsDMARD were included from the prospective NOR-DMARD study. Controls were randomly drawn from the general population. Cox regressions were used to compare the 12-month risk of serious infections across three time cohorts following initiation (2009-2011, 2012-2014, 2015-2018) and risk during the course of treatment at 6-month intervals up to 24 months.

SUBMITTER: Christensen IE 

PROVIDER: S-EPMC11889454 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature